Full antagonism of the estrogen receptor without a prototypical ligand side chain

Sathish Srinivasan, Jerome C. Nwachukwu, Nelson E. Bruno, Venkatasubramanian Dharmarajan, Devrishi Goswami, Irida Kastrati, Scott Novick, Jason Nowak, Valerie Cavett, Hai Bing Zhou, Nittaya Boonmuen, Yuechao Zhao, Jian Min, Jonna Frasor, Benita S Katzenellenbogen, Patrick R. Griffin, John A. Katzenellenbogen, Kendall W. Nettles

Research output: Contribution to journalArticle

Abstract

Resistance to endocrine therapies remains a major clinical problem for the treatment of estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms. A series of crystal structures and phenotypic assays reveal a structure-based design strategy with separate design elements for antagonism and degradation of the receptor, and access to a structurally distinct space for further improvements in ligand design. Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metabolism, and autoimmunity.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalNature chemical biology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Estrogen Receptors
Ligands
Breast Neoplasms
Chemoprevention
Therapeutic Uses
Therapeutics
Autoimmunity
Energy Metabolism
Compliance
Estrogens
Homeostasis
Phenotype
Bone and Bones
Health

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Srinivasan, S., Nwachukwu, J. C., Bruno, N. E., Dharmarajan, V., Goswami, D., Kastrati, I., ... Nettles, K. W. (2017). Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nature chemical biology, 13(1), 111-118. https://doi.org/10.1038/nchembio.2236

Full antagonism of the estrogen receptor without a prototypical ligand side chain. / Srinivasan, Sathish; Nwachukwu, Jerome C.; Bruno, Nelson E.; Dharmarajan, Venkatasubramanian; Goswami, Devrishi; Kastrati, Irida; Novick, Scott; Nowak, Jason; Cavett, Valerie; Zhou, Hai Bing; Boonmuen, Nittaya; Zhao, Yuechao; Min, Jian; Frasor, Jonna; Katzenellenbogen, Benita S; Griffin, Patrick R.; Katzenellenbogen, John A.; Nettles, Kendall W.

In: Nature chemical biology, Vol. 13, No. 1, 01.01.2017, p. 111-118.

Research output: Contribution to journalArticle

Srinivasan, S, Nwachukwu, JC, Bruno, NE, Dharmarajan, V, Goswami, D, Kastrati, I, Novick, S, Nowak, J, Cavett, V, Zhou, HB, Boonmuen, N, Zhao, Y, Min, J, Frasor, J, Katzenellenbogen, BS, Griffin, PR, Katzenellenbogen, JA & Nettles, KW 2017, 'Full antagonism of the estrogen receptor without a prototypical ligand side chain', Nature chemical biology, vol. 13, no. 1, pp. 111-118. https://doi.org/10.1038/nchembio.2236
Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I et al. Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nature chemical biology. 2017 Jan 1;13(1):111-118. https://doi.org/10.1038/nchembio.2236
Srinivasan, Sathish ; Nwachukwu, Jerome C. ; Bruno, Nelson E. ; Dharmarajan, Venkatasubramanian ; Goswami, Devrishi ; Kastrati, Irida ; Novick, Scott ; Nowak, Jason ; Cavett, Valerie ; Zhou, Hai Bing ; Boonmuen, Nittaya ; Zhao, Yuechao ; Min, Jian ; Frasor, Jonna ; Katzenellenbogen, Benita S ; Griffin, Patrick R. ; Katzenellenbogen, John A. ; Nettles, Kendall W. / Full antagonism of the estrogen receptor without a prototypical ligand side chain. In: Nature chemical biology. 2017 ; Vol. 13, No. 1. pp. 111-118.
@article{176a65eada304489a8872d6939a77c8a,
title = "Full antagonism of the estrogen receptor without a prototypical ligand side chain",
abstract = "Resistance to endocrine therapies remains a major clinical problem for the treatment of estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms. A series of crystal structures and phenotypic assays reveal a structure-based design strategy with separate design elements for antagonism and degradation of the receptor, and access to a structurally distinct space for further improvements in ligand design. Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metabolism, and autoimmunity.",
author = "Sathish Srinivasan and Nwachukwu, {Jerome C.} and Bruno, {Nelson E.} and Venkatasubramanian Dharmarajan and Devrishi Goswami and Irida Kastrati and Scott Novick and Jason Nowak and Valerie Cavett and Zhou, {Hai Bing} and Nittaya Boonmuen and Yuechao Zhao and Jian Min and Jonna Frasor and Katzenellenbogen, {Benita S} and Griffin, {Patrick R.} and Katzenellenbogen, {John A.} and Nettles, {Kendall W.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/nchembio.2236",
language = "English (US)",
volume = "13",
pages = "111--118",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Full antagonism of the estrogen receptor without a prototypical ligand side chain

AU - Srinivasan, Sathish

AU - Nwachukwu, Jerome C.

AU - Bruno, Nelson E.

AU - Dharmarajan, Venkatasubramanian

AU - Goswami, Devrishi

AU - Kastrati, Irida

AU - Novick, Scott

AU - Nowak, Jason

AU - Cavett, Valerie

AU - Zhou, Hai Bing

AU - Boonmuen, Nittaya

AU - Zhao, Yuechao

AU - Min, Jian

AU - Frasor, Jonna

AU - Katzenellenbogen, Benita S

AU - Griffin, Patrick R.

AU - Katzenellenbogen, John A.

AU - Nettles, Kendall W.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Resistance to endocrine therapies remains a major clinical problem for the treatment of estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms. A series of crystal structures and phenotypic assays reveal a structure-based design strategy with separate design elements for antagonism and degradation of the receptor, and access to a structurally distinct space for further improvements in ligand design. Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metabolism, and autoimmunity.

AB - Resistance to endocrine therapies remains a major clinical problem for the treatment of estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms. A series of crystal structures and phenotypic assays reveal a structure-based design strategy with separate design elements for antagonism and degradation of the receptor, and access to a structurally distinct space for further improvements in ligand design. Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metabolism, and autoimmunity.

UR - http://www.scopus.com/inward/record.url?scp=84996879351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996879351&partnerID=8YFLogxK

U2 - 10.1038/nchembio.2236

DO - 10.1038/nchembio.2236

M3 - Article

VL - 13

SP - 111

EP - 118

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 1

ER -